Advertisement

Topics

Transthyretin ATTR or Prealbumin or TBPA or TTR Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

22:18 EST 11 Nov 2017 | BioPortfolio Reports

Transthyretin ATTR or Prealbumin or TBPA or TTR Pipeline Review, H2 2017


Summary


According to the recently published report 'Transthyretin ATTR or Prealbumin or TBPA or TTR Pipeline Review, H2 2017'; Transthyretin ATTR or Prealbumin or TBPA or TTR pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.


Transthyretin ATTR or Prealbumin or TBPA or TTR Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol vitamin A in the plasma. The diseases caused by mutations include amyloidotic polyneuropathy, euthyroid hyperthyroxinaemia, amyloidotic vitreous opacities, cardiomyopathy, oculoleptomeningeal amyloidosis, meningocerebrovascular amyloidosis and carpal tunnel syndrome.


The report 'Transthyretin ATTR or Prealbumin or TBPA or TTR Pipeline Review, H2 2017' outlays comprehensive information on the Transthyretin ATTR or Prealbumin or TBPA or TTR targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Transthyretin ATTR or Prealbumin or TBPA or TTR targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2, 2 and 5 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Central Nervous System and Cardiovascular which include indications Familial Amyloid Neuropathies, Amyloidosis, Amyloid Cardiomyopathy, Familial Amyloid Cardiomyopathy, Alzheimer's Disease, Cardiomyopathy and Neuropathy.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Transthyretin ATTR or Prealbumin or TBPA or TTR

The report reviews Transthyretin ATTR or Prealbumin or TBPA or TTR targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Transthyretin ATTR or Prealbumin or TBPA or TTR targeted therapeutics and enlists all their major and minor projects

The report assesses Transthyretin ATTR or Prealbumin or TBPA or TTR targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transthyretin ATTR or Prealbumin or TBPA or TTR targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transthyretin ATTR or Prealbumin or TBPA or TTR

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transthyretin ATTR or Prealbumin or TBPA or TTR development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Transthyretin ATTR or Prealbumin or TBPA or TTR Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Transthyretin ATTR or Prealbumin or TBPA or TTR Pipeline Review, H2 2017 [Report Updated: 10102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...